Tianjin, China

Weiren Xu

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 11.5

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2010-2022

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Weiren Xu: Innovator in Pharmaceutical Research

Introduction

Weiren Xu is a prominent inventor based in Tianjin, China, known for his significant contributions to pharmaceutical research. With a total of 10 patents to his name, he has made remarkable advancements in the field of drug development.

Latest Patents

One of his latest patents is focused on thienopyridine derivatives containing unsaturated aliphatic olefinic bonds. This invention provides a compound with a specific structure, a preparation method, and its use in pharmaceutical compositions. The compound addresses critical issues such as clopidogrel resistance and severe hemorrhagic side effects, offering a potential solution with improved stability and therapeutic effects. Another notable patent involves a crystal form of a urate transporter 1 inhibitor, which enhances the purity and storage stability of the compound, making it suitable as a pharmaceutical raw material.

Career Highlights

Weiren Xu has worked at the Tianjin Institute of Pharmaceutical Research and the Tianjin Institute of Pharmaceutical Research Co., Ltd. His work has been instrumental in developing innovative pharmaceutical solutions that address various medical challenges.

Collaborations

Throughout his career, Weiren has collaborated with notable colleagues, including Lida Tang and Yuli Wang. Their combined expertise has contributed to the success of various research projects and patent developments.

Conclusion

Weiren Xu's contributions to pharmaceutical research and his innovative patents highlight his role as a leading inventor in the industry. His work continues to pave the way for advancements in drug development and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…